Sweden
Slogan: Committed to developing and commercializing long-acting treatments for patients with severe and chronic diseases.
Description: Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology, and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.
Founded: 1991
Industries: Health Care, Pharmaceutical
Headquarter: Sweden
Last Investment: €54.00MVenture Round investment at 23 November 2015 by Erik Paulsson, Martin Gren
As a Swedish biopharmaceutical company, Camurus has established a strong presence in developing and commercializing long-acting treatments for severe and chronic diseases. With a diverse clinical pipeline and proprietary FluidCrystal® drug delivery technologies, they offer innovative solutions in the areas of opioid dependence, chronic pain, rare diseases, oncology, and supportive care. Their successful listing on Nasdaq Stockholm and the support from investors such as Erik Paulsson and Martin Gren indicate a promising trajectory for the company in the health care and pharmaceutical industries.
